The Influence of the Neuromuscular Blockade on Mask Ventilation; a Placebo Controlled, Randomized Trial With Three Different Dosages of Rocuronium (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg)

Trial Profile

The Influence of the Neuromuscular Blockade on Mask Ventilation; a Placebo Controlled, Randomized Trial With Three Different Dosages of Rocuronium (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2016

At a glance

  • Drugs Rocuronium bromide (Primary)
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2016 Status changed from recruiting to completed.
    • 21 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 21 Oct 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top